This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Medidata Solutions Inc. Stock Downgraded (MDSO)

NEW YORK ( TheStreet) -- Medidata Solutions (Nasdaq: MDSO) has been downgraded by TheStreet Ratings from buy to hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the company's profit margins have been poor overall.

Highlights from the ratings report include:

  • The gross profit margin for MEDIDATA SOLUTIONS INC is currently very high, coming in at 72.90%. Regardless of MDSO's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 7.80% trails the industry average.
  • Net operating cash flow has significantly increased by 489.55% to $5.76 million when compared to the same quarter last year. In addition, MEDIDATA SOLUTIONS INC has also vastly surpassed the industry average cash flow growth rate of 13.55%.
  • MEDIDATA SOLUTIONS INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. This trend suggests that the performance of the business is improving. During the past fiscal year, MEDIDATA SOLUTIONS INC increased its bottom line by earning $0.96 versus $0.22 in the prior year. This year, the market expects an improvement in earnings ($1.43 versus $0.96).
  • Powered by its strong earnings growth of 62.50% and other important driving factors, this stock has surged by 53.62% over the past year, outperforming the rise in the S&P 500 Index during the same period. Although MDSO had significant growth over the past year, our hold rating indicates that we do not recommend additional investment in this stock at the current time.

Medidata Solutions, Inc. provides software-as-a-service based clinical development solutions for life science organizations worldwide. The company has a P/E ratio of 23.6, above the average computer software & services industry P/E ratio of 23.4 and above the S&P 500 P/E ratio of 17.7. Medidata has a market cap of $573.2 million and is part of the technology sector and computer software & services industry. Shares are down 1.6% year to date as of the close of trading on Thursday.

You can view the full Medidata Ratings Report or get investment ideas from our investment research center.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
Submit an article to us!

Markets

DOW 17,894.64 +89.84 0.50%
S&P 500 2,070.75 +0.10 0.00%
NASDAQ 4,769.1480 +3.7680 0.08%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs